tobiasmenne (@tobiasmenne2) 's Twitter Profile
tobiasmenne

@tobiasmenne2

Haematologist- Clinical Director for Research; Honorary Senior Lecturer Newcastle University; Member: national adult ALL, low and high grade lymphoma subgroups

ID: 972083957872431105

linkhttp://www.newcastle-hospitals.org.uk/staff-profiles/15254.aspx calendar_today09-03-2018 12:17:30

211 Tweet

575 Takipçi

212 Takip Edilen

tobiasmenne (@tobiasmenne2) 's Twitter Profile Photo

Great to see that RVI and Freeman Hospitals are ranked 2nd and 4th best hospitals in the UK. RVI score of 90.9 is close to the 10th best hospital in the USA

Great to see that RVI and Freeman Hospitals are ranked 2nd and 4th best hospitals in the UK. RVI score of 90.9 is close to the 10th best hospital in the USA
Toby Eyre (@tobyeyre82) 's Twitter Profile Photo

ReMODEL-B: Davies et al. Outstanding e.g. of Cancer Research UK funded RCT using real time GEP COO (+IPI) to stratify+randomise 1L #DLBCL pts btwn RCHOP vs Bortezomib-RCHOP cycle 2 onwards. No diff in PFS but proof of principle truely established. Congratulations to Peter Johnson et al #lymsm

ReMODEL-B: Davies et al. Outstanding e.g. of <a href="/CR_UK/">Cancer Research UK</a> funded RCT using real time GEP COO (+IPI) to stratify+randomise 1L #DLBCL pts btwn RCHOP vs Bortezomib-RCHOP cycle 2 onwards. No diff in PFS but proof of principle truely established. Congratulations to <a href="/PWMJohnson/">Peter Johnson</a> et al #lymsm
Toby Eyre (@tobyeyre82) 's Twitter Profile Photo

Sibon et al. Pooled analysis 263 ALK+ALCL. In a #lymphoma where RCTs are challenging+with retrospective caveats, this is pretty convincing data (esp<60yr) that argues for adding etoposide in 1L in ALK+ALCL (BV/Echelon-2 aside!). IPI remains strong PFS/OS predictor. #blooducation

Sibon et al. Pooled analysis 263 ALK+ALCL. In a #lymphoma where RCTs are challenging+with retrospective caveats, this is pretty convincing data (esp&lt;60yr) that argues for adding etoposide in 1L in ALK+ALCL (BV/Echelon-2 aside!). IPI remains strong PFS/OS predictor. #blooducation
Lymphoma Papers (@lymphoma_papers) 's Twitter Profile Photo

Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma. #lymphoma #lymsm bit.ly/2vWq4Td

tobiasmenne (@tobiasmenne2) 's Twitter Profile Photo

#ASH19 Jurinovic et al really interesting observation from Gallium study patients with EZH2 mutated FL had much better responses to CHOP based chemo than Benda based suggest R/G CHOP in this setting and R-Benda for non EZH2 mutated FL - needs to be confirmed in other studies

#ASH19 Jurinovic et al really interesting observation from Gallium study patients with EZH2 mutated FL had much better responses to CHOP based chemo than Benda based suggest R/G CHOP in this setting and R-Benda for non EZH2 mutated FL - needs to be confirmed in other studies
tobiasmenne (@tobiasmenne2) 's Twitter Profile Photo

Obinutuzumab and lenalidomide 30mg phase 2 study Nathan Fowler et al • 57 R/r FL 9 all/MZL • good response rates even in rituximab refractory setting •toxicity acceptable •PFS promising Interesting data need to be confirmed in randomised study #ASH19 #lymsm

Obinutuzumab and lenalidomide 30mg phase 2 study
Nathan Fowler et al

• 57 R/r FL 9 all/MZL
• good response rates even in rituximab refractory setting
•toxicity acceptable
•PFS promising

Interesting data need to be confirmed in randomised study
#ASH19 #lymsm
tobiasmenne (@tobiasmenne2) 's Twitter Profile Photo

UK election Conservative party 43.6% of the total UK votes yet they have 55.8% of the seats. How is this democratic!!! Proportional representation is a much fairer system

tobiasmenne (@tobiasmenne2) 's Twitter Profile Photo

Truly amazing news, Emma!!! Warmest congratulations and cordial wishes for a long and happy life to you all. Very humbled by the honour, Tobias

NICE (@nicecomms) 's Twitter Profile Photo

Today we’ve published draft guidance recommending lenalidomide (Revlimid) as the first maintenance treatment for people with newly diagnosed multiple myeloma. Read the draft guidance here: bit.ly/3acjRX3

Today we’ve published draft guidance recommending lenalidomide (Revlimid) as the first maintenance treatment for people with newly diagnosed multiple myeloma. Read the draft guidance here: bit.ly/3acjRX3
tobiasmenne (@tobiasmenne2) 's Twitter Profile Photo

Will be fascinating to see at ASH. What is OS and PFS difference between R-CHOP and R-CHP+Pola. Ash21 could have several game changers in DLBCL. Polarix for 1L and Transform and Zuma-7 for 2L. Can’t wait to see all these study data.

tobiasmenne (@tobiasmenne2) 's Twitter Profile Photo

I am honoured to have been appointed as the new Clinical Director for Research Newcastle Hospitals Newcastle Hospitals Research from September. I will do my utmost best to implement our new strategic priorities to further boost our excellent tradition of Clinical Research at NUTH

tobiasmenne (@tobiasmenne2) 's Twitter Profile Photo

Game changing study. E1910. RCT in frontline Ph neg B-ALL addition of blinatumomab consolidation improves significantly OS and EFS in MRD2 neg and positive setting #ASH2022 Blina consolidation should be new SOC

Game changing study.               E1910. RCT in frontline Ph neg B-ALL addition of blinatumomab consolidation improves significantly OS and EFS in MRD2 neg and positive setting #ASH2022    Blina consolidation should be new SOC
Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo

I just attended one of the biggest cancer meetings in the world. #ASH22 ASH For my followers here is a snapshot of the incredible progress happening with cancer treatment. It’s good. Thread.